Related Experiment Video
Updated: May 22, 2026
06:02
Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
Published on: July 26, 2011
Native PLGA nanoparticles attenuate disease pathology via multiple pathways in 5xFAD Alzheimer's model
Govindarajan Karthivashan1, Shuai Wang2, Qi Wu1
1Department of Medicine (Neurology), Centre for Prions and Protein Folding Diseases, University of Alberta, Edmonton, Alberta, Canada.
Summary
Native poly(D,L-lactic-co-glycolic acid) (PLGA) nanoparticles improved cognition and reduced amyloid pathology in Alzheimer
Area of Science:
- Neuroscience
- Biomaterials Science
- Pharmacology
Background:
- Alzheimer's disease (AD) is linked to amyloid beta (Aβ) aggregation and neurotoxicity.
- Poly(D,L-lactic-co-glycolic acid) (PLGA) nanoparticles are clinically used for drug delivery.
- Previous studies showed PLGA suppresses Aβ aggregation, but effects in advanced AD models were unknown.
Purpose of the Study:
- To investigate the therapeutic potential of native PLGA nanoparticles in adult 5xFAD mice with established Alzheimer's disease pathology.
- To assess the impact of PLGA on cognitive function, amyloid burden, synaptic integrity, and neurodegeneration.
Main Methods:
- Chronic intracerebroventricular (ICV) infusion of native PLGA in 8-month-old male 5xFAD mice.
- Assessment of cognitive function, amyloid levels, synaptic integrity, and neurodegenerative markers.
- Bulk RNA sequencing (RNA-seq) to analyze transcriptional changes in brain tissue.
Main Results:
- PLGA treatment significantly reversed cognitive deficits in 5xFAD mice.
- Reduced amyloid beta (Aβ) levels, deposits, and neurodegenerative events were observed.
- Transcriptional analysis revealed PLGA modulated Aβ production, oxidative stress, lysosomal clearance, vesicle trafficking, immune activity, and redox regulation.
Conclusions:
- Native PLGA nanoparticles demonstrate therapeutic potential for Alzheimer's disease.
- PLGA targets multiple facets of the amyloid beta (Aβ) pathway, including production, clearance, and associated neuroinflammation.
- PLGA offers a promising strategy for treating AD-related pathology.
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...